These results demonstrate that the combination of CDK4/6i and radiotherapy is a potentially effective strategy not just for ER+ breast cancers, but for the radiosensitization of other RB1 WT cancers including TNBC, which have disproportionately high rates of locoregional recurrence after RT. The gene discussed is ESR1; the disease is breast cancer.